Copyright 2002 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2002
To the Editor: Xu et al1
previously reported that lysophosphatidic acid (LPA) levels are increased
in the plasma of patients with ovarian cancer, and they proposed that LPA
may be a useful early marker of ovarian cancer. Other studies have also reported
that LPA levels are increased in malignant effusions in patients with cancer,2,3 particularly of the ovaries.4 To assess the utility of LPA as a marker of ovarian
cancer, we measured the amount of LPA in plasma from patients with ovarian
cancer and from healthy control subjects, as well as LPA levels in fluid from
Baker DL, Morrison P, Miller B, et al. Plasma Lysophosphatidic Acid Concentration and Ovarian Cancer. JAMA. 2002;287(23):3081–3082. doi:10.1001/jama.287.23.3077
Customize your JAMA Network experience by selecting one or more topics from the list below.